Induction of Adhesion-Inhibitory Antibodies against Placental Plasmodium falciparum Parasites by Using Single Domains of VAR2CSA
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
In areas of endemicity pregnancy-associated malaria is an important cause of maternal anemia, stillbirth, and delivery of low-birth-weight children. The syndrome is precipitated by the accumulation of Plasmodium falciparum-infected erythrocytes in the placenta, mediated through an interaction between a parasite protein expressed on erythrocytes named variant surface antigen 2-chondroitin sulfate A (VAR2CSA) and CSA on syncytiotrophoblasts. VAR2CSA is a large polymorphic protein consisting of six Duffy binding-like (DBL), domains and with current constraints on recombinant protein production it is not possible to produce entire VAR2CSA recombinant proteins. Furthermore, the presence of polymorphisms has raised the question of whether it is feasible to define VAR2CSA antigens eliciting broadly protective antibodies. Thus, the challenge for vaccine development is to define smaller parts of the molecule which induce antibodies that inhibit CSA binding of different parasite strains. In this study, we produced a large panel of VAR2CSA proteins and raised antibodies against these antigens. We show that antibodies against the DBL4 domain effectively inhibit parasite binding. As the inhibition was not limited to homologous parasite strains, it seems feasible to base a protective malaria vaccine on a single VAR2CSA DBL domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, antibodies to the single DBL4 domain almost completely inhibited the binding of homologous and 2 heterologous IE to CSA [47,48] while antibodies to other single or multi-domain immunogens only reduced homologous parasite binding to CSA by 50–60% [47].”
From Designing a VAR2CSA-based vaccine to prevent placental malaria (2015) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome sequence of the human malaria parasite Plasmodium falciparum
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002) · Nature · doi:10.1038/nature01097 · Cited by 4,407
Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta
Fried, M., & Duffy, P. E. (1996) · Science · doi:10.1126/science.272.5267.1502 · Cited by 1,108 · cited 1×
“Pregnancy-associated malaria (PAM) is caused by IE that sequester in the intervillous space of the placenta by adhering to chondroitin sulfate A (CSA) (8).”
BackgroundSalanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702 · cited 1×
“Placental parasites and parasite lines selected for CSA binding in vitro express a unique var gene named var2csa (20, 24).”
BackgroundSelf-citationMaternal antibodies block malaria
Fried, M., Nosten, F., Brockman, A., Brabin, B. J., & Duffy, P. E. (1998) · Nature · doi:10.1038/27570 · Cited by 659 · cited 1×
“can prevent parasites from other regions in the world from adhering to CSA (10), further suggesting that the antigenic targets of protective immunity are conserved.”
BackgroundMalaria in pregnancy: pathogenesis and immunity
Rogerson, S. J., Hviid, L., Duffy, P. E., Leke, R. F., & Taylor, D. W. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70022-1 · Cited by 628
Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria
Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041579 · Cited by 604 · cited 8×
“The antigen is expressed on the surface of IE panned on CSA in vitro and on ex vivo IE isolated from infected placentas (13, 19).”
BackgroundInfluentialSelf-citationTolia, N. H., Enemark, E. J., Sim, B. K. L., & Joshua-Tor, L. (2005) · Cell · doi:10.1016/j.cell.2005.05.033 · Cited by 330 · cited 1×
“It has been shown that the two DBL domains of EBA-175 can form a dimer and that the glycan-ligand interacts at the dimer interface (23); if VAR2CSA glycan interaction is also dependent on domain dimerization, a possible mechanism of the blocking antibodies could be to hinder this dimerization.”
BackgroundFried, M., Muga, R., Misore, A. O., & Duffy, P. E. (1998) · PubMed · Cited by 321
Staalsoe, T., Shulman, C. E., Bulmer, J. N., Kawuondo, K., Marsh, K., & Hviid, L. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15386-x · Cited by 288 · cited 1×
“Women in areas where malaria is endemic acquire antibodies that protect against PAM as a function of parity (22).”
BackgroundFried, M., Muga, R. O., Misore, A. O., & Duffy, P. E. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2523 · Cited by 262
Cited by
Bacterial superglue enables easy development of efficient virus-like particle based vaccines
Thrane, S., Janitzek, C. M., Matondo, S., Resende, M., Gustavsson, T., de Jongh, W. A., Clemmensen, S., Roeffen, W., van de Vegte‑Bolmer, M., van Gemert, G. J., et al. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0181-1 · Cited by 203
“Inhibition of binding assays Plasmodium falciparum (FCR3 genotype) parasites were maintained in culture as described [60].”
MethodSelf-citationClausen, T. M., Christoffersen, S., Dahlbäck, M., Langkilde, A. E., Jensen, K. E., Resende, M., Agerbæk, M. Ø., Andersen, D., Berisha, B., Ditlev, S. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348839 · Cited by 173
“The same has been shown for several CSA-binding multidomain fragments, as well as single domain non-CSA binding fragments (DBL4 ) (19, 34, 35).”
BackgroundSelf-citationChan, J.-A., Fowkes, F. J. I., & Beeson, J. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1614-3 · Cited by 168
“Furthermore, antibodies generated against full-length [160, 281] and single domains of vAR2CSA [282] by immunisation inhibited adhesion of Ies to CSA, suggesting that vaccine-induced antibodies may have a protective function in vivo.”
BackgroundSrivastava, A., Gangnard, S., Round, A., Dechavanne, S., Juillerat, A., Raynal, B., Faure, G., Baron, B., Ramboarina, S., Singh, S. K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000951107 · Cited by 149
“Indeed, combining our results with those recently reported, showing an absence of CSA-binding for FCR3-DBL4ε (25) but a strong inhibition of PE binding to CSA in the presence of anti-DBL4ε antibodies (20), suggests that this var2CSAdomain does not participate directly in receptor binding but rather contributes to the…”
BackgroundKhunrae, P., Dahlbäck, M., Nielsen, M. A., Andersen, G., Ditlev, S. B., Resende, M., Pinto, V. V., Theander, T. G., Higgins, M. K., & Salanti, A. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.01.040 · Cited by 121
“Anti-DBL4ɛ IgG was the same IgG used by Nielsen et al.(14)”
BackgroundMethodSelf-citationFunctional Antibodies and Protection against Blood-stage Malaria
Teo, A., Feng, G., Brown, G. V., Beeson, J. G., & Rogerson, S. J. (2016) · Trends in Parasitology · doi:10.1016/j.pt.2016.07.003 · Cited by 147
Strategies for Designing and Monitoring Malaria Vaccines Targeting Diverse Antigens
Barry, A. E., & Arnott, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00359 · Cited by 130
“Furthermore, antibodies against major surface antigens cross-react with different parasite strains including those from different geographic areas suggesting that conserved epitopes exist (65, 124).”
BackgroundProtective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin
Ndam, N. T., Denoeud-Ndam, L., Doritchamou, J., Viwami, F., Salanti, A., Nielsen, M. A., Fievet, N., Massougbodji, A., Luty, A. J. F., & Deloron, P. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2105.141626 · Cited by 98
“The full-length ectodomain of VAR2CSA (FV2) from the FCR3 strain and the truncation corresponding to Duffy binding-like (DBL) antigen (DBL1–DBL2 encompassing 2 domains, DBL3, DBL4, DBL5, and DBL6 domains) were produced in baculovirus-infected SF9 cells as described (11,19,29).”
Self-citationDesigning a VAR2CSA-based vaccine to prevent placental malaria
Fried, M., & Duffy, P. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.011 · Cited by 86
“The N-terminal region of VAR2CSA, NTS–DBL1–ID1–DBL2, elicited antibodies that almost completely inhibited the binding of homologous FCR3 and heterologous HB3 IE [52], consistent with an earlier study reporting anti-adhesion activity by antibodies raised against multidomain immunogens including NTS–DBL1–ID1–DBL2 [47].”
BackgroundResultInfluentialThe Chondroitin Sulfate A-binding Site of the VAR2CSA Protein Involves Multiple N-terminal Domains
Dahlbäck, M., Jørgensen, L. M., Nielsen, M. A., Clausen, T. M., Ditlev, S. B., Resende, M., Pinto, V. V., Arnot, D. E., Theander, T. G., & Salanti, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.191510 · Cited by 85
Self-citationAdvances and challenges in malaria vaccine development
Wang, R., Smith, J. D., & Kappe, S. H. I. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001318 · Cited by 87
Var2CSA minimal CSA binding region is located within the N-terminal region
Srivastava, A., Gangnard, S., Dechavanne, S., Amirat, F., Lewit Bentley, A., Bentley, G. A., & Gamain, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020270 · Cited by 76
“This hypothesis is supported by our observations that the single domain DBL5e also retained inhibitory antibodies and that DBL3X-4e was more effective than DBL3X, and almost as effective as DBL1X-3X, in retaining inhibitory antibodies, suggesting that DBL4e is also a target of inhibitory antibodies, as previously repo…”
BackgroundResultInfluentialHviid, L. (2010) · Human Vaccines · doi:10.4161/hv.6.1.9602 · Cited by 75
Tutterrow, Y. L., Avril, M., Singh, K., Long, C. A., Leke, R. J., Sama, G., Salanti, A., Smith, J. D., Leke, R. G. F., & Taylor, D. W. (2012) · Infection and Immunity · doi:10.1128/iai.00071-12 · Cited by 65
“histidine tag at the C-terminal end (41).”
Self-citationSander, A. F., Salanti, A., Lavstsen, T., Nielsen, M. A., Magistrado, P., Lusingu, J., Ndam, N. T., & Arnot, D. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006667 · Cited by 64
Self-citationBigey, P., Gnidehou, S., Doritchamou, J., Quiviger, M., Viwami, F., Couturier, A., Salanti, A., Nielsen, M. A., Scherman, D., Deloron, P., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir499 · Cited by 63
Self-citationBarfod, L., Dobrilovic, T., Magistrado, P., Khunrae, P., Viwami, F., Bruun, J., Dahlbäck, M., Bernasconi, N. L., Fried, M., John, D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002390 · Cited by 62
“In this context, it is worth noticing that antisera against DBL4-ε (not implicated in CSA adhesion) also strongly inhibit adhesion of IEs to CSA (24).”
BackgroundResultSelf-citationKhunrae, P., Philip, J. M. D., Bull, D. R., & Higgins, M. K. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.027 · Cited by 61
“Indeed, antibodies raised against the individual domains of VAR2CSA reduce the binding of infected erythrocytes to CSA.(30,31) This suggests that the interaction between VAR2CSA and CSPG is the principal target for development of therapeutics to target placental malaria.”
BackgroundInfluentialA Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA
Thrane, S., Janitzek, C. M., Agerbæk, M. Ø., Ditlev, S. B., Resende, M., Nielsen, M. A., Theander, T. G., Salanti, A., & Sander, A. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143071 · Cited by 67
“The VAR2CSA antigen has previously been shown to induce functional antibodies when adsorbed to aluminum hydroxide [35] and Freund’s complete adjuvant [23].”
BackgroundMethodSelf-citationGhumra, A., Khunrae, P., Ataíde, R., Raza, A., Rogerson, S. J., Higgins, M. K., & Rowe, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016414 · Cited by 60
“However, in the case of CSA-binding, although single domains of the var2CSA PfEMP1 variant do bind CSA, the full-length molecule binds with 10,000 fold higher affinity [41,51].”
BackgroundMethodInfluentialJanitzek, C. M., Peabody, J., Thrane, S., Carlsen, P. H. R., Theander, T. G., Salanti, A., Chackerian, B., Nielsen, M. A., & Sander, A. F. (2019) · Scientific Reports · doi:10.1038/s41598-019-41522-5 · Cited by 62
Self-citationAitken, E. H., Damelang, T., Ortega-Pajares, A., Alemu, A., Hasang, W., Dini, S., Unger, H. W., Ome‐Kaius, M., Nielsen, M. A., Salanti, A., et al. (2021) · eLife · doi:10.7554/elife.65776 · Cited by 50
Self-citationMagistrado, P. A., Minja, D., Doritchamou, J., Tuikue Ndam, N., John, D., Schmiegelow, C., Massougbodji, A., Dahlbäck, M., Ditlev, S. B., Pinto, V. V., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.10.080 · Cited by 49
Self-citationNielsen, M. A., Resende, M., de Jongh, W. A., Ditlev, S. B., Mordmüller, B., Houard, S., Ndam, N. T., Agerbæk, M. Ø., Hamborg, M., Massougbodji, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135406 · Cited by 48
“Adult Wistar rats (Taconic) were injected via the sub-cutaneous route with 40 μg of recombinant protein in PBS and Freund’s complete adjuvant (Sigma-Aldrich) or Alhydrogel (Statens Serum Institute) followed by two booster injections of 20 μg of protein in Freund's incomplete adjuvant or Alhydrogel at 3-week intervals…”
MethodSelf-citationMayor, A., Kumar, U., Bardají, A., Gupta, P., Jiménez, A., Hamad, A., Sigaúque, B., Singh, B., Quintó, L., Kumar, S., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit083 · Cited by 45
Turner, L., Wang, C. W., Lavstsen, T., Mwakalinga, S., Sauerwein, R. W., Hermsen, C. C., & Theander, T. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029025 · Cited by 49
Self-citationRieger, H., Yoshikawa, H., Quadt, K. A., Nielsen, M. A., Sanchez, C. P., Salanti, A., Tanaka, M., & Lanzer, M. (2014) · Blood · doi:10.1182/blood-2014-03-561019 · Cited by 52
Self-citationSeveral domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies
Salanti, A., Resende, M., Ditlev, S. B., Pinto, V. V., Dahlbäck, M., Andersen, G., Manczak, T., Theander, T. G., & Nielsen, M. A. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-11 · Cited by 42
“Cloning and expression of VAR2CSA DBL proteins To identify other domains than the published DBL4FCR3 [21], which could induce inhibitory antibodies, all single domains from 3D7 VAR2CSA and HB3 VAR2CSA were cloned (Table 1).”
InfluentialSelf-citationPlasmodium falciparum Expressing Domain Cassette 5 Type PfEMP1 (DC5-PfEMP1) Bind PECAM1
Berger, S. S., Turner, L., Wang, C. W., Petersen, J. E. V., Kraft, M., Lusingu, J., Mmbando, B. P., Marquard, A. M., Bengtsson, D. C., Hviid, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069117 · Cited by 49
“So far, only one receptor: ligand pair, the binding of VAR2CSA to Chondroitin Sulfate A (CSA) [30] has been unambiguously associated with a particular malaria complication: the sequestration of parasites in the placenta leading to severe malaria in pregnant women [31,32].”
BackgroundInfluentialSelf-citationIgM, FcμRs, and Malarial Immune Evasion
Czajkowsky, D. M., Salanti, A., Ditlev, S. B., Shao, Z., Ghumra, A., Rowe, J. A., & Pleass, R. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000203 · Cited by 43
“Interference with neutralizing and adhesion-blocking Abs Rosetting and placental parasite isolates may also bind nonspecific IgM to allow masking of critical PfEMP1 domains from the destructive action of specific Abs, e.g., IgG.”
MethodInfluentialSelf-citationAvril, M., Hathaway, M. J., Srivastava, A., Dechavanne, S., Hommel, M., Beeson, J. G., Smith, J. D., & Gamain, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016622 · Cited by 40
“To date, the most potent inhibitory antibodies response has been generated against the highly conserved DBL4 domain [43], but induction has not been consistently achieved against different VAR2CSA DBL4 alleles [42,43].”
BackgroundInfluentialProgress and Insights Toward an Effective Placental Malaria Vaccine
Gamain, B., Chêne, A., Viebig, N. K., Ndam, N. T., & Nielsen, M. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634508 · Cited by 46
Self-citationAvril, M., Cartwright, M. M., Hathaway, M. J., Hommel, M., Elliott, S. R., Williamson, K., Narum, D. L., Duffy, P. E., Fried, M., Beeson, J. G., et al. (2010) · Infection and Immunity · doi:10.1128/iai.00410-09 · Cited by 39
“In that report, immunization of rats with any of the six VAR2CSA-DBL domains could elicit adhesion-inhibitory antibodies, but the best inhibitory antibodies were made against a VAR2CSA-DBL4 recombinant protein and were partially inhibitory against two heterologous parasite isolates (36).”
BackgroundMultilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria
Fried, M., Avril, M., Chaturvedi, R., Fernandez, P., Lograsso, J., Narum, D., Nielsen, M. A., Oleinikov, A. V., Resende, M., Salanti, A., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01106-12 · Cited by 38
“The DBL4 domain of the FCR3 allelic form almost completely inhibited FCR3 parasite binding to CSA (17, 34, 35).”
BackgroundSelf-citationCytoadhesion to gC1qR through Plasmodium falciparum Erythrocyte Membrane Protein 1 in Severe Malaria
Magallón-Tejada, A., Machevo, S., Cisteró, P., Lavstsen, T., Aíde, P., Rubio, M., Jiménez, A., Turner, L., Valmaseda, A., Gupta, H., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006011 · Cited by 42
“Third, the conditions of the binding assay may not allow for 100% inhibition as has been shown for other receptors [32,61].”
BackgroundBordbar, B., Ndam, N. T., Bigey, P., Doritchamou, J., Scherman, D., & Deloron, P. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.065 · Cited by 43
Fernandez, P., Petres, S., Mécheri, S., Gysin, J., & Scherf, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012558 · Cited by 36
“In addition only very limited parasite inhibition using DBL5-specific serum was obtained in another laboratory (DBL5-e produced in the baculovirus expression system) [18].”
BackgroundDoritchamou, J. Y. A., Herrera, R., Aebig, J. A., Morrison, R., Nguyen, V., Reiter, K., Shimp, R. L., MacDonald, N. J., Narum, D. L., Fried, M., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw197 · Cited by 35
The case for PfEMP1-based vaccines to protect pregnant women against Plasmodium falciparum malaria
Hviid, L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.113 · Cited by 34
Patel, J. C., Hathaway, N. J., Parobek, C. M., Thwai, K. L., Madanitsa, M., Khairallah, C., Kalilani‐Phiri, L., Mwapasa, V., Massougbodji, A., Fiévet, N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04737-y · Cited by 37
Pehrson, C., Mathiesen, L., Heno, K. K., Salanti, A., Resende, M., Dzikowski, R., Damm, P., Hansson, S. R., King, C. L., Schneider, H., et al. (2016) · Malaria Journal · doi:10.1186/s12936-016-1342-2 · Cited by 37
“Currently, adhesion blocking capacity of antibodies has largely been tested in assays where only one receptor, namely CSA, is present [20–22], however the efficacy of such antibodies may be limited if sequestration occurs by other pathways.”
BackgroundSelf-citationUtilizing nanobody technology to target non-immunodominant domains of VAR2CSA
Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084981 · Cited by 31
“These domains were produced using a baculo-virus expression system, as described in [11,20].”
Self-citationAvril, M., Cartwright, M. M., Hathaway, M. J., & Smith, J. D. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-36 · Cited by 35
“Immunization of animals with single domain VAR2CSA recombinant proteins produced in Baculovirus [26], Escherichia coli [27,28] and Pichia pastoris [29,30] demonstrate that it is possible to generate antibodies reactive with native VAR2CSA at the IE surface.”
BackgroundInfluentialDoritchamou, J., Bigey, P., Nielsen, M. A., Gnidehou, S., Ezinmegnon, S., Burgain, A., Massougbodji, A., Deloron, P., Salanti, A., & Ndam, N. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.072 · Cited by 29
Self-citationHeparan Sulfate Proteoglycans in Infection
Bartlett, A. H., & Park, P. W. (2011) · Springer eBooks · doi:10.1007/978-3-642-16833-8_2 · Cited by 33
Can any lessons be learned from the ambiguous glycan binding of PfEMP1 domains?
Dahlbäck, M., Nielsen, M. A., & Salanti, A. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2010.02.002 · Cited by 32
Self-citationMolecular Principles of Intrauterine Growth Restriction in Plasmodium Falciparum Infection
Seitz, J., Prieto, D. M. M., Fávaro, R. R., Schneider, H., & Markert, U. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00098 · Cited by 36
Singh, K., Gitti, R. K., Diouf, A., Zhou, H., Gowda, D. C., Miura, K., Ostazeski, S. A., Fairhurst, R. M., Garboczi, D. N., & Long, C. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118612 · Cited by 26
Sander, A. F., Salanti, A., Lavstsen, T., Nielsen, M. A., Theander, T. G., Leke, R. G. F., Lo, Y. Y., Bobbili, N., Arnot, D. E., & Taylor, D. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir168 · Cited by 25
Self-citationGangnard, S., Lewit-Bentley, A., Dechavanne, S., Srivastava, A., Amirat, F., Bentley, G. A., & Gamain, B. (2015) · Scientific Reports · doi:10.1038/srep14868 · Cited by 25
Pre-clinical and clinical development of the first placental malaria vaccine
Pehrson, C., Salanti, A., Theander, T. G., & Nielsen, M. A. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322512 · Cited by 34
Self-citationAntigen Reversal Identifies Targets of Opsonizing IgGs against Pregnancy-Associated Malaria
Lambert, L. H., Bullock, J. L., Cook, S. T., Miura, K., Garboczi, D. N., Diakité, M., Fairhurst, R. M., Singh, K., & Long, C. A. (2014) · Infection and Immunity · doi:10.1128/iai.02097-14 · Cited by 27
Doritchamou, J., Sabbagh, A., Jespersen, J. S., Renard, E., Salanti, A., Nielsen, M. A., Deloron, P., & Tuikue Ndam, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137695 · Cited by 22
Self-citationDeveloping vaccines to prevent malaria in pregnant women
Ndam, N. T., & Deloron, P. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1049595 · Cited by 30
“Sequence analysis within the DBL2X region, a domain that seems pivotal in the optimal construct [70,74], highlighted two distinct phylogenetic subgroups discriminating two subfamily sequences, one close to the 3D7 strain and the other one close to the FCR3 strain [90].”
BackgroundObiakor, H., Avril, M., MacDonald, N. J., Srinivasan, P., Reiter, K., Anderson, C., Holmes, K. L., Fried, M., Duffy, P. E., Smith, J. D., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00638-12 · Cited by 22
“Conversely, most single-domain antigens, with the exception of DBL4ε and DBL5ε, have elicited limited adhesion blocking activity (28, 29, 30, 31, 32).”
BackgroundOptimizing expression of the pregnancy malaria vaccine candidate, VAR2CSA in Pichia pastoris
Avril, M., Hathaway, M. J., Cartwright, M. M., Gose, S. O., Narum, D. L., & Smith, J. D. (2009) · Malaria Journal · doi:10.1186/1475-2875-8-143 · Cited by 23
“All three expression systems are being investigated for VAR2CSA vaccine development [18,19,21, 26 ], but only a subset of the DBL domains have been analysed in E. coli and P. pastoris because of difficulty in producing some recombinant proteins.”
BackgroundAugustyniak, D., Majkowska-Skrobek, G., Roszkowiak, J., & Dorotkiewicz‐Jach, A. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170508110222 · Cited by 20
Acute response to pathogens in the early human placenta at single-cell resolution
Hoo, R., Ruiz-Morales, E. R., Kelava, I., Rawat, M., Icoresi-Mazzeo, C., Tuck, E. J., Sancho‐Serra, C., Chelaghma, S., Predeus, A. V., Murray, S., et al. (2024) · Cell Systems · doi:10.1016/j.cels.2024.04.002 · Cited by 26
Kane, E. G., & Taylor-Robinson, A. W. (2011) · Malaria Research and Treatment · doi:10.4061/2011/764845 · Cited by 22
“It has proved difficult for study groups to adequately assess binding of different DBL regions, as interactions between recombinant proteins (expressed by Escherichia coli, baculovirus or Pichia pastoris constructs [220–222]) and CSA in vitro may not be representative of native binding [223].”
BackgroundTwo-Faced Immunity? The Evidence for Antibody Enhancement of Malaria Transmission
Stone, W. J., Bousema, T., Sauerwein, R. W., & DRAKELEY, C. J. (2018) · Trends in Parasitology · doi:10.1016/j.pt.2018.11.003 · Cited by 19
Pinto, V. V., Ditlev, S. B., Jensen, K. E., Resende, M., Dahlbäck, M., Andersen, G., Andersen, P., Theander, T. G., Salanti, A., & Nielsen, M. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017942 · Cited by 18
“Differential recognition of DBL4e in ELISA-peptide array analysis The DBL4e recombinant protein appeared previously to be the only single domain that induces highly inhibitory antibodies [15].”
BackgroundMethodSelf-citationProgress and new horizons toward a VAR2CSA-based placental malaria vaccine
Doritchamou, J., Suurbaar, J., & Ndam, N. T. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1878029 · Cited by 21
Wang, W., Wang, Z., Yang, X., Gao, Y., Zhang, X., Wang, W., Zhao, L., zhang, J., Jing, Q., Xu, Q., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00324-8 · Cited by 19
Impact of Malaria in Pregnancy as Latin America Approaches Elimination
Yanow, S. K., Gavina, K., Gnidehou, S., & Maestre, A. (2016) · Trends in Parasitology · doi:10.1016/j.pt.2016.01.008 · Cited by 20
“These antibodies, either from multigravid women or from animals vaccinated with VAR2CSA, efficiently inhibit binding to CSA of parasitized red cells from pregnant women [67] or P. falciparum laboratory strains expressing VAR2CSA [68].”
InfluentialPinto, V. V., Salanti, A., Joergensen, L., Dahlbäck, M., Resende, M., Ditlev, S. B., Agger, E. M., Arnot, D. E., Theander, T. G., & Nielsen, M. A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.068 · Cited by 17
Self-citationStructural insights into chondroitin sulfate binding in pregnancy-associated malaria
Khunrae, P., & Higgins, M. K. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381337 · Cited by 18
Andersson, A.-M. C., Resende, M., Salanti, A., Nielsen, M. A., & Holst, P. J. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.01.016 · Cited by 14
Self-citationSaveria, T., Oleinikov, A. V., Wiliamson, K., Chaturvedi, R., Lograsso, J., Keitany, G. J., Fried, M., & Duffy, P. E. (2013) · Infection and Immunity · doi:10.1128/iai.00978-12 · Cited by 15
“to CSA on the surface of placental cells (19, 20).”
BackgroundInfluentialGullingsrud, J., Milman, N., Saveria, T., Chesnokov, O., Williamson, K., Srivastava, A., Gamain, B., Duffy, P. E., & Oleinikov, A. V. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu589 · Cited by 13
“DBL domain constructs from the FCR3 and 7G8 laboratory strains were also shown to recognize and inhibit CSA binding of some laboratory and field isolates [26–29].”
BackgroundGangnard, S., Ndam, N. T., Gnidehou, S., Quiviger, M., Juillerat, A., Faure, G., Baron, B., Viwami, F., Deloron, P., & Bentley, G. A. (2010) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2010.05.014 · Cited by 15
Identification and Characterization of B-Cell Epitopes in the DBL4ε Domain of VAR2CSA
Ditlev, S. B., Nielsen, M. A., Resende, M., Agerbæk, M. Ø., Pinto, V. V., Andersen, P. H., Magistrado, P., Lusingu, J., Dahlbäck, M., Theander, T. G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043663 · Cited by 11
Self-citationMa, R., Salinas, N. D., Orr-Gonzalez, S., Richardson, B., Ouahes, T., Torano, H., Jenkins, B. J., Dickey, T. H., Neal, J., Duan, J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011879 · Cited by 12
Comparison of functional assays used in the clinical development of a placental malaria vaccine
Pehrson, C., Heno, K. K., Adams, Y., Resende, M., Mathiesen, L., Søgaard, M., de Jongh, W. A., Theander, T. G., Salanti, A., & Nielsen, M. A. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.12.028 · Cited by 13
“Rat (Wistar (inbred), Taconic, Denmark) antisera were produced as previously described [30].”
MethodSelf-citationSheean, M. E., Malikova, E., Duarte, D. M., Capovilla, G., Fregonese, L., Hofer, M. P., Magrelli, A., Mariz, S., Mendez-Hermida, F., Nisticò, R., et al. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.10.015 · Cited by 10
Development of vaccines to prevent malaria in pregnant women: WHO MALVAC meeting report
Menéndez, C., Moorthy, V., Reed, Z. H., Bardají, A., Alonso, P. L., & Brown, G. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.95 · Cited by 8
Babakhanyan, A., Tutterrow, Y. L., Bobbili, N., Salanti, A., Wey, A. R., Fogako, J., LEKE, R. J. I., Leke, R. G. F., & Taylor, D. W. (2015) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.15-0521 · Cited by 10
Self-citationAPPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
García‐Basteiro, A. L., Bassat, Q., & Alonso, P. L. (2012) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2012.015 · Cited by 16
High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites
Nielsen, M. A., & Salanti, A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2815-6_20 · Cited by 12
Self-citationEvaluation of Pregnancy Malaria Vaccine Candidates: The Binding Inhibition Assay
Saveria, T., Duffy, P. E., & Fried, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2815-6_19 · Cited by 11
“Several platforms for binding inhibition assays have been described, including a highthroughput assay in 96-well plates of tritium-labeled parasites [5] and a flow-based assay [6].”
MethodA VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses
Matondo, S., Thrane, S., Janitzek, C. M., Kavishe, R. A., Mwakalinga, S., Theander, T. G., Salanti, A., Nielsen, M. A., & Sander, A. F. (2017) · African Health Sciences · doi:10.4314/ahs.v17i2.11 · Cited by 10
Self-citationHow specific is Plasmodium falciparum adherence to chondroitin 4-sulfate?
Goel, S., & Gowda, D. C. (2011) · Trends in Parasitology · doi:10.1016/j.pt.2011.03.005 · Cited by 10
Iyamu, U., Vinals, D. F., Tornyigah, B., Arango, E., Bhat, R., Adra, T. R., Grewal, S., Martin, K., Maestre, A., Overduin, M., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1202276 · Cited by 7
VAR2CSA Antibodies in Non-Pregnant Populations
Gnidehou, S., & Yanow, S. K. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.09.012 · Cited by 8
Antigenic Variation, Adherence, and Virulence in Malaria
Smith, J. D., & Deitsch, K. (2012) · Wiley eBooks · doi:10.1002/9781118308165.ch18 · Cited by 6
Guillotte-Blisnick, M., Juillerat, A., Igonet, S., Hessel, A., Pêtres, S., Crublet, E., Scanf, C. L., Lewit‐Bentley, A., Bentley, G. A., Vigan-Womas, I., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134292 · Cited by 5
“Endpoint titres for all domains were higher than those usually reported for PfEMP1-Var2CSA individual domains injected in Freund's adjuvant [23, 24, 34], including studies that reported improved immunogenicity and higher ELISA titres [31, 32, 34].”
Vanda, K., Bobbili, N., Matsunaga, M., Chen, J. J., Salanti, A., Leke, R. F. G., & Taylor, D. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.610108 · Cited by 4
“Characteristics of the recombinant proteins have been detailed previously (23, 24).”
BackgroundSelf-citationBordbar, B., Gnidehou, S., Ndam, N. T., Doritchamou, J., Moussiliou, A., Quiviger, M., Deloron, P., Scherman, D., & Bigey, P. (2011) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2011.12.009 · Cited by 3
mSphere of Influence: Structural Insights into the Molecular Mechanism Underlying Placental Malaria
Quintana, M. D. P. (2021) · mSphere · doi:10.1128/msphere.00391-21 · Cited by 2
Malaria, Hepatitis B and Their Co-Infection Among Pregnant Women Visiting Maternity Centers in AkurePreprint
Afolabi, O. J., & Bakare, T. P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3961257 · Cited by 2
Approaching the Target: the Path Towards
García‐Basteiro, A. L., Bassat, Q., García, A. L., & Alonso, P. L. (2012)
Rovira-Vallbona, E. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Horii, T., & Palacpac, N. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735412890.793573195
Metadata
- Authors
- Nielsen, M. A., Pinto, V. V., Resende, M., Dahlbäck, M., Ditlev, S. B., Theander, T. G., & Salanti, A.
- Affiliations
- University of Copenhagen (DK)
- Centre for Medical Parasitology at Department of International Health, Immunology, and Microbiology, University of Copenhagen, and at Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark
- Corresponding author
- Salanti, Ali
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2009-06
- Volume
- 77
- Issue
- 6
- Pages
- 2482-2487
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- PMC
- PMC2687338
- OpenAlex
- W2145844769
- Cited by
- 92
- References
- 26
- Citations by year
- 2024: 2 · 2023: 1 · 2021: 7 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 7 · 2015: 11 · 2014: 6 · 2013: 5 · 2012: 8
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Infection and Immunity (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Keywords
- VAR2CSA, Plasmodium falciparum, malaria in pregnancy, placental adhesions, Duffy binding-like domain, chondroitin sulfate A, malaria vaccine development, antigenic polymorphism
- MeSH terms
- Animals, Antibodies, Protozoan, Antigens, Protozoan, Cell Adhesion, Humans, Plasmodium falciparum, Trophoblasts, Malaria Vaccines, Vaccines, Subunit, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.